3,388 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Tema Etfs LLC

Tema Etfs LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 3,388 shares of the biopharmaceutical company’s stock, valued at approximately $283,000.

A number of other large investors also recently added to or reduced their stakes in ITCI. Barclays PLC lifted its stake in Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 25,435 shares in the last quarter. Park Avenue Securities LLC lifted its stake in Intra-Cellular Therapies by 21.3% during the fourth quarter. Park Avenue Securities LLC now owns 6,293 shares of the biopharmaceutical company’s stock worth $526,000 after purchasing an additional 1,103 shares in the last quarter. Avanza Fonder AB acquired a new position in Intra-Cellular Therapies during the fourth quarter worth $254,000. Merit Financial Group LLC acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at $206,000. Finally, Oak Ridge Investments LLC raised its stake in shares of Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after acquiring an additional 8,440 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. StockNews.com assumed coverage on Intra-Cellular Therapies in a research note on Thursday. They issued a “hold” rating on the stock. Mizuho cut Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Finally, Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and increased their price objective for the company from $119.00 to $132.00 in a research note on Friday, January 31st. Eleven investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Stock Performance

Shares of ITCI stock opened at $131.87 on Monday. The stock’s 50-day moving average is $131.79 and its two-hundred day moving average is $114.22. The firm has a market cap of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 1 year low of $64.09 and a 1 year high of $131.98.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings data on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. As a group, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.